Annual General Meeting in Pharmexa A/S
April 27, 2006 12:47 ET
|
Pharmexa A/S
HORSHOLM, Denmark, April 27, 2006 (PRIMEZONE) -- The General Meeting approved the report of the Board of Directors and the Financial Statements.
The Board of Directors' motion that the loss for the...
Pharmexa Files the First Phase III Application
February 01, 2006 03:20 ET
|
Pharmexa A/S
HOERSHOLM, Denmark, Feb. 1, 2006 (PRIMEZONE) -- Pharmexa has filed an application to obtain approval to initiate the phase III trial with GV1001 in Ireland. Further applications will be filed in a...
Pharmexa to Acquire Certain Assets from IDM Pharma and Establishes U.S. Subsidiary
November 24, 2005 02:31 ET
|
Pharmexa A/S
HORSHOLM, Denmark, Nov. 24, 2005 (PRIMEZONE) -- Pharmexa Summary:
-- Pharmexa A/S ("Pharmexa") and IDM Pharma, Inc. ("IDM") have entered
into an agreement whereby Pharmexa will acquire...
Pharmexa: Interim Report for the First Six Months of 2005
August 24, 2005 07:55 ET
|
Pharmexa A/S
HORSHOLM, Denmark, Aug. 24, 2005 (PRIMEZONE) -- Summary: The Pharmexa Group generated revenue of DKK 1,756 thousand in the first six months of 2005 and realised a net loss of DKK 59,065 thousand....
Pharmexa: Promising Preliminary Results with Breast Cancer Vaccine
August 16, 2005 08:41 ET
|
Pharmexa A/S
HORSHOLM, Denmark, Aug. 16, 2005 (PRIMEZONE) -- Summary: Pharmexa has seen promising preliminary results from a phase II trial of the company's breast cancer vaccine and received approval to start an...
H. Lundbeck and Pharmexa enter into option agreement
January 23, 2004 03:43 ET
|
Pharmexa A/S
HORSHOLM, Denmark, Jan. 23, 2004 (PRIMEZONE) -- H. Lundbeck and Pharmexa have entered into an option agreement, whereby H. Lundbeck will invest DKK 10 million on the same terms as other shareholders...
Pharmexa announces positive data from a clinical trial with the HER-2 Protein AutoVac(TM) breast cancer vaccine
January 19, 2004 06:50 ET
|
Pharmexa A/S
HORSHOLM, Denmark, Jan. 19, 2004 (PRIMEZONE) -- Pharmexa has completed the first clinical trial with HER-2 Protein AutoVac(TM) in 10 breast cancer patients in the US. The data show that the vaccine...
Pharmexa announces promising preliminary data from a clinical trial with the HER-2 Protein AutoVac breast cancer vaccine
November 20, 2003 04:05 ET
|
Pharmexa A/S
HORSHOLM, Denmark, Nov. 20, 2003 (PRIMEZONE) -- Pharmexa -- Summary: The preliminary data from a phase I trial with the HER-2 Protein AutoVac(TM) vaccine in 10 breast cancer patients in the US...
Pharmexa A/S: New Analysis of Data from TNF-alpha AutoVac Clinical Trial Shows Clear Antibody Levels
November 17, 2003 09:30 ET
|
Pharmexa A/S
HORSHOLM, Denmark, Nov. 17, 2003 (PRIMEZONE) -- Summary: A new analysis shows that a TNF-alpha vaccine based on Pharmexa's (Other OTC:PMXAY) AutoVac(TM) technology induced antibodies in approximately...
Pharmexa Reports Progress in U.S. Breast Cancer Trial
September 10, 2003 09:43 ET
|
Pharmexa A/S
HORSHOLM, Denmark, Sept. 10, 2003 (PRIMEZONE) -- Summary: Recruitment of patients to the US phase I breast cancer trial with Pharmexa's (Other OTC:PMXAY) HER-2 AutoVac(TM) Protein vaccine has now...